Abstract
In this report, select key studies presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting are reviewed. Two major phase III randomized controlled trials were presented at the meeting: GEINO 1401 and EORTC 1709/CCTG CE.8. Both are reviewed in this report. Moreover, important phase II trials, including Alliance A0716701, and key phase I trials are included. All trials presented cover important advances in the understanding of primary brain tumor management. In addition, case series papers, trials in progress and select work on exploratory CSF biomarkers are reviewed. Altogether, research presented at ASCO 2021 highlights important advances in neuro-oncologic topics that may inform future research and practice.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4425-4429 |
| Number of pages | 5 |
| Journal | Future Oncology |
| Volume | 17 |
| Issue number | 33 |
| DOIs | |
| State | Published - Nov 2021 |
Funding
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. NIH funding: Rimas V Lukas, Priya Kumthekar, and Amy B Heimberger are all supported by: P50 CA221747 (CA/NCI NIH HHS/United States). No writing assistance was utilized in the production of this manuscript.
Keywords
- brain metastases
- craniopharyngioma
- glioblastoma
- leptomeningeal metastases
- meeting report
- neuro-oncology
ASJC Scopus subject areas
- Oncology
- Cancer Research
